We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+5.45%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$243M
AUM Growth
+$6.44M
(+2.7%)
Cap. Flow
-$803K
Cap. Flow
% of AUM
-0.33%
Top 10 Holdings %
Top 10 Hldgs %
7.68%
Holding
410
New
55
Increased
156
Reduced
186
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BKCC
BlackRock Capital Investment Corporation
BKCC
|
+$673K |
| 2 |
Zai Lab
ZLAB
|
+$472K |
| 3 |
Stellus Capital Investment Corp
SCM
|
+$422K |
| 4 |
DRD
DRDGold
DRD
|
+$415K |
| 5 |
OXLC
Oxford Lane Capital
OXLC
|
+$359K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AMRS
Amyris Inc.
AMRS
|
+$1.16M |
| 2 |
RUBY
Rubius Therapeutics, Inc
RUBY
|
+$664K |
| 3 |
BioNTech
BNTX
|
+$663K |
| 4 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
+$645K |
| 5 |
Prothena Corp
PRTA
|
+$590K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 27.38% |
| 2 | Real Estate | 18.81% |
| 3 | Energy | 13.29% |
| 4 | Materials | 10.7% |
| 5 | Utilities | 10.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Viking Therapeutics
VKTX
$4.16B
| $220K | 0.09% |
36,791
-7,964
| -18% | -$47.3K |
|
277
Q32 Bio
QTTB
$455M
| $220K | 0.09% |
1,682
+288
| +21% | +$35.9K |
|
278
Ascendis Pharma A/S
ASND
$16.7B
| $219K | 0.09% |
1,664
+23
| +1% | +$3.06K |
|
279
Phathom Pharmaceuticals
PHAT
$951M
| $219K | 0.09% |
6,476
-277
| -4% | -$9.92K |
|
|
DRNA
280
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $219K | 0.09% |
5,880
-6,272
| -52% | -$192K |
|
281
Compugen
CGEN
$225M
| $218K | 0.09% |
26,285
+3,049
| +13% | +$24.8K |
|
|
CMPS
282
Compass Pathways
CMPS
$1.53B
| $218K | 0.09% |
+5,724
| New | +$204K |
|
283
Geron
GERN
$949M
| $218K | 0.09% |
154,267
-18,324
| -11% | -$26.6K |
|
284
Mirum Pharmaceuticals
MIRM
$6.98B
| $218K | 0.09% |
12,602
+87
| +0.7% | +$1.56K |
|
285
Fate Therapeutics
FATE
$284M
| $216K | 0.09% |
2,486
-624
| -20% | -$50.3K |
|
286
Sutro Biopharma
STRO
$397M
| $216K | 0.09% |
1,164
-217
| -16% | -$42.5K |
|
|
GTHX
287
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $216K | 0.09% |
9,832
-5,487
| -36% | -$122K |
|
288
Annovis Bio
ANVS
$71.9M
| $215K | 0.09% |
+2,518
| New | +$116K |
|
289
Annexon
ANNX
$867M
| $214K | 0.09% |
9,515
-2,656
| -22% | -$58.9K |
|
290
BridgeBio Pharma
BBIO
$16.6B
| $214K | 0.09% |
3,509
-1,393
| -28% | -$79.6K |
|
|
ETNB
291
DELISTED
89bio
ETNB
| $214K | 0.09% |
11,442
+91
| +0.8% | +$2.03K |
|
292
ImmunityBio
IBRX
$7.32B
| $214K | 0.09% |
14,982
-10,868
| -42% | -$180K |
|
293
IDEAYA Biosciences
IDYA
$3.52B
| $214K | 0.09% |
+10,177
| New | +$209K |
|
294
Kymera Therapeutics
KYMR
$9.16B
| $214K | 0.09% |
+4,421
| New | +$192K |
|
295
Lexicon Pharmaceuticals
LXRX
$973M
| $214K | 0.09% |
+46,699
| New | +$225K |
|
|
MRNS
296
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $214K | 0.09% |
11,930
-10,982
| -48% | -$177K |
|
|
ADVM
297
DELISTED
Adverum Biotechnologies
ADVM
| $213K | 0.09% |
6,079
+3,935
| +184% | +$212K |
|
298
Black Diamond Therapeutics
BDTX
$101M
| $213K | 0.09% |
17,462
+8,706
| +99% | +$172K |
|
299
Immatics
IMTX
$1.2B
| $213K | 0.09% |
18,350
-12,708
| -41% | -$149K |
|
|
RNAM
300
DELISTED
Avidity Biosciences
RNAM
| $213K | 0.09% |
8,613
-525
| -6% | -$12.2K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q2 2021 Portfolio in Review
As of Q2 2021, Virtus ETF Advisers held 410 positions worth $243M, up 2.7% from $237M the previous quarter. Its ten largest holdings account for 7.7% of the portfolio.
Virtus ETF Advisers's Q2 2021 filing shows 55 new, 156 increased, 186 reduced and 11 closed positions. Its largest new stake was Zai Lab: 2,937 shares worth $520K. The largest sale was Amyris Inc., an estimated $1.16M.
By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 30% a quarter earlier, followed by Real Estate and Energy.
- Virtus ETF Advisers's largest Q2 2021 buy was Zai Lab: 2,937 shares worth $520K.
- Virtus ETF Advisers added most to BlackRock Capital Investment Corporation in Q2 2021, an estimated $673K increase.
- Virtus ETF Advisers's biggest Q2 2021 reduction was Amyris Inc., cutting an estimated $1.16M.
- Virtus ETF Advisers fully exited Five Prime Therapeutics, Inc. in Q2 2021, selling an estimated $645K.
- Virtus ETF Advisers's ten largest holdings make up 7.7% of its $243M portfolio in Q2 2021.
- Virtus ETF Advisers opened 55 new positions and closed 11 in Q2 2021.
- Virtus ETF Advisers's portfolio value rose 2.7% quarter-over-quarter to $243M.
Based on Virtus ETF Advisers's 13F filing for Q2 2021, filed 10 Aug 2021.